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Abstract: Currently, insulin can only be administered through the subcutaneous route. Due to the 
flaws associated with this route, it is of interest to orally deliver this drug. However, insulin 
delivered orally has several barriers to overcome as it is degraded by the stomach’s low pH, 
enzymatic content, and poor absorption in the gastrointestinal tract. Polymers with marine source 
like chitosan are commonly used in nanotechnology and drug delivery due to their biocompatibility 
and special features. This work focuses on the preparation and characterization of mucoadhesive 
insulin-loaded polymeric nanoparticles. Results showed a suitable mean size for oral administration 
(<600 nm by dynamic laser scattering), spherical shape, encapsulation efficiency (59.8%), and high 
recovery yield (80.6%). Circular dichroism spectroscopy demonstrated that protein retained its 
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secondary structure after encapsulation. Moreover, the mucoadhesive potential of the nanoparticles 
was assessed in silico and the results, corroborated with ex-vivo experiments, showed that using 
chitosan strongly increases mucoadhesion. Besides, in vitro and in vivo safety assessment of the 
final formulation were performed, showing no toxicity. Lastly, the insulin-loaded nanoparticles 
were effective in reducing diabetic rats’ glycemia. Overall, the coating of insulin-loaded 
nanoparticles with chitosan represents a potentially safe and promising approach to protect insulin 
and enhance peroral delivery. 
Keywords: marine-derived biomolecules; diabetes mellitus; insulin; mucoadhesion; nanoparticle; 
oral delivery 
 
1. Introduction 
Diabetes mellitus is a group of metabolic disorders that arise from defective action and/or 
secretion of insulin, resulting in hyperglycemia [1]. Type 1 diabetes is characterized by the life-long 
need of exogenous insulin replacement. These patients have the need to self-administer long-acting 
insulin in order to establish basal levels, and short-acting insulin before meals [2,3]. Insulin 
administration is done by subcutaneous injection or by constant subcutaneous infusions [3]. 
Although this route is considered the only option for insulin therapy, and very efficient and broadly 
used, there are drawbacks and disadvantages associated with its usage [4,5]. Some of these include 
lipoatrophy and lipohypertrophy on the injection site and discomfort [6]. In addition, all tissues are 
being exposed to equal quantities of insulin [7], being that insulin reaches the muscles and adipocytes 
prior to the liver [8], with only around 20% of the administered insulin reaching this target organ [9]. 
The peripheral hyperglycemia might lead to unwanted overstimulation of the metabolic responses 
[6]. When insulin is administered subcutaneously, it is first distributed to the peripheral tissues [10]. 
Thus, this route of administration does not mimic the endogenous insulin produced by the islets of 
Langerhans by non-diabetics. When administered orally, exogenous insulin is absorbed in the 
intestine, reaching the liver through the portal vein and inhibiting hepatic glucose output, mimicking 
the physiological pathway by undergoing hepatic first passage [10,11]. Although oral delivery of 
insulin is the most comfortable and convenient route for the patient, it also has difficulties associated 
with its usage due to its protein nature [12]. Such difficulties include poor absorption by the intestine 
epithelium due to insulin’s hydrophilicity and large dimensions, as well as insulin degradation due 
to the pH and enzymes in the stomach and small intestine [10,13], leading to low bioavailability [14].  
To this date, many efforts have been done to try to improve oral administration of insulin, 
including the use of nanoparticles (NPs) [15,16]. NPs may overcome the mentioned difficulties by 
protecting the protein drug from the hostile conditions of the gastrointestinal tract (GIT) and 
improving its absorption [14]. This can be achieved by adjusting the surface charge, shape, size, and 
hydrophobicity of the NPs, and other characteristics [17]. Furthermore, the use of NPs allows control 
over the drug release [17,18]. Previous reports have shown that using synthetic and/or natural 
polymers to nanoencapsulate insulin improves its absorption in the intestine [17,19]. Moreover, by 
choosing the correct materials to prepare the nanoformulation, certain beneficial characteristics can 
be achieved. The developed insulin formulation for oral delivery entails insulin-loaded poly (D, L-
lactic-co-glycolic acid) (PLGA) NPs coated with chitosan and polyethylene glycol (PEG), with an 
external coating composed of bovine serum albumin (BSA). PLGA is widely used as a nanocarrier, 
because it is biodegradable and, when in combination with polyethylene glycol (PEG), allows for 
longer plasmatic circulation time [20]. The addition of (BSA), as an outer coat of the NPs, acts as a 
protective layer against proteolytic enzymes of the GIT, allowing insulin to reach systemic circulation 
intact and increasing its bioavailability at its absorption site [21–23], i.e., the intestine. But one of the 
most important biomolecules in this work comes from the sea. In this case, the ocean has been shown 
to provide a rich place with great biodiversity and chemical entities with proven bioactivities. 
Chitosan is generally derived from the shells of shrimp and other sea crustaceans and it acts as a 
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permeability enhancer by opening the tight junctions of the intestinal epithelium, facilitating 
paracellular and transcellular transport [23–25]. Moreover, chitosan prolongs the residence of time of 
chitosan-coated formulations in mucosae, through its interactions with mucins [26,27]. 
This work focuses on preparation and characterization of double-coated insulin-loaded NPs by 
using the following techniques: dynamic light scattering and electrophoretic mobility for size and 
surface charge analysis, respectively; scanning electron microscopy to assess the NPs’ surface; HPLC 
for determination of encapsulation efficiency; circular dichroism to evaluate insulin’s activity after 
the encapsulation and ex-vivo and in silico studies to access the mucoadhesion. Safety assessment 
was in vitro preliminarily assessed using cells and then by in vivo using animal models. Finally, the 
efficacy of the formulation was in vivo assessed by evaluating the effect of glycemia in diabetic rats 
following oral administration of the double-coated insulin-loaded NPs. 
2. Materials and Methods  
2.1. Materials 
2.1.1. Chemicals  
Pluronic® F167 (POLX), pepsin (250 IU/mL), BSA (MW 66 kDa) and PEG 4000 were acquired 
from Sigma-Aldrich (St. Louis, MO, USA). PURASORB® PDLG 5002- PLGA Ratio L/G% 50:50 (MW 
45,000–75,000 Da) was purchased from Purac (Gorinchem, The Netherlands). Chitosan from crab 
shells with low molecular weight (Aldrich), 75–85% deacetylated, was used [27]. The insulin used 
was Insuman Rapid (Sanofi, Paris, France), a fast-acting insulin, at a concentration of 100 IU/mL. 
Water MiliQ by Millipore Corporation (Burlington, MA, USA). All the chemical products and 
solvents used are of analytic purity grade. 
2.1.2. Animals 
Male Wistar rats 8–10-weeks old, with an average weight of 200 g, were purchased from Charles 
River (Barcelona, Spain). Males were chosen over female Wistar rats due to the potential influence of 
female hormones over insulin sensitivity [28]. The animal housing was kept at the controlled 
temperature of 22.0 ± 1.0 °C, humidity at 50.0 ± 15.0% and a cycle of light of 12 h. Animals were kept 
under standard hygiene conditions, fed with commercial chow and given acidified drinking water 
ad libitum. The feed was removed 12 h prior to the day of treatment. 
All animal experiments (Protocol title: Improvement of insulin oral availability through 
encapsulation in polyelectrolyte complex nanoparticles, n.° POCI/SAU-FCF//59940) was conducted 
in accordance with the EU Directive (2010/63/UE), the Portuguese law (DR 113/2013, 2880/2015 and 
260/2016) and the Animal Welfare Commission of the Faculty of Pharmacy, University of Coimbra, 
approved by Ethics Committee of the Faculty of Pharmacy, University of Coimbra and by the 
competent national authority Direcção-Geral de Alimentação e Veterinária (DGAV). 
2.2. Methods 
2.2.1. Preparation of NPs 
The NPs were prepared according to the modified-spontaneous emulsification solvent diffusion 
method [29]. An organic solution containing PLGA and insulin was prepared in a non-aqueous 
solvent mixture. The latter suspension was gradually added to an aqueous solution containing a 
surfactant at 0.1%, POLX, dissolved in water, at pH 4.5, at room temperature (25 °C) and stirred at 
800 rpm (Heidolph MR3001, Heidolph Instruments, Schwabach, Germany), for 15 min [30]. All 
parameters were considered based on previous studies reported [29,30]. Next, the NPs were coated 
with a chitosan aqueous solution (0.03% w/v, previously solubilized with glacial acetic acid at 1%) 
enriched with PEG (0.150%, w/v), by mixing the previous solution with an aqueous solution 
containing these compounds. This was done at room temperature, and the NPs were constantly 
stirred at a speed of 180 rpm, for 30 min. Then, the coated NPs were re-coated with a BSA aqueous 
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solution, at a concentration of 1 g/mL, by stirring the chitosan-NPs solutions with this aqueous 
solution at a speed of 100 rpm, for 30 min. After the final coating, the formulation was centrifuged at 
10.000× g, for 15 min (Beckman Instruments centrifuge, Inc., Brea, CA, USA), in order to remove all 
the reagents that did not react. 
2.2.2. NPs Characterization 
Mean Size, Polydispersity Index (PI), and Zeta Potential Analysis 
The uncoated NPs, chitosan-coated NPs and double-coated NPs were characterized regarding 
their mean particle size, polydispersity index (PdI) and surface charge as zeta potential. Particle size 
and PdI were measured in diluted samples with water MiliQ (1:10, v/v) using Dynamic Light 
Scattering (Zetasizer Nano S, Malvern Instruments, Malvern, Worcestershire, UK), and performed in 
triplicates. Zeta potential was analyzed using an electrophoretic mobility assay using the same 
equipment, using NPs diluted in water MiliQ (same dilution). 
Surface and Morphological Analysis 
The morphology of single-coated and double-coated NPs was observed by Scanning Electron 
Microscopy (SEM). Aliquots (10 µL) of particle suspensions were scattered over round glass 
coverslips coated with poly L-lysine, that were previously attached with a double face tape to the 
microscope stubs. The samples, after dying in a desiccator, were coated with a thin layer of gold and 
observed on a JEOL 5200 LV scanning electron microscope (JEOL Ltd., Tokyo, Japan) at 20 kV. The 
images were digitally recorded.  
2.2.3. Determination of Encapsulation Efficiency (EE) 
The percentage of insulin encapsulated was determined indirectly by quantifying the amount of 
insulin present in the supernatant after centrifugation of samples (10.000× g, 15 min; using a Beckman 
Instruments centrifuge, Inc., Brea, California). This quantification was done by HPLC (Hitachi System 
LaCrom Elite, Column oven, Diode Array Detector Uv-vis and Pump, Tokyo, Japan), using a Column 
Waters Symmetry C18, 5 μm 4.6 × 150 mm, with an isocratic flow of 0.7 mL/min. The mobile phase 
was composed by acetonitrile:TFA water (60:40) (v/v). The measurements were performed in 
triplicates and the calibration was done with a standardized solution of insulin, at 220 nm 
wavelength. The linearity range was established in the 1.09 – 70 μg/mL range and the detection limit 
was 0.359 µg/mL and the quantification limit was 1.087 µg/mL. The retention time was equal to 3.1 
min. Encapsulation efficiency (EE, %) was then determined by using Equation 1: 
 
  (%) =
(                        −                                )
                       
× 100 (1
) 
2.2.4. Determination of Recovery Yield (RY) 
NPs were recovered after being centrifuged and lyophilized at −49 °C for at least 48 h (Freezone 
2.5 L, Freeze-dryer Labconco, Kansas City, MO, USA). Next, NPs were stored at 4 °C, according to 
previous works [29]. The recovery yield (RY, %) was determined using Equation 2: 
   (%) =  
                           
                                      
× 100 (2) 
2.2.5. Insulin Activity 
Circular Dichroism (CD) 
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The secondary structure of insulin was analyzed by CD spectroscopy. Circular dichroism (CD) 
spectra were recorded on a JASCO J-720 spectropolarimeter (JASCO, Hiroshima, Japan) with a 180–
700 nm photomultiplier (EXEL-308). CD spectra were recorded in the far UV range from 260 to 200 
nm with quartz Suprasil® CD cuvettes (0.1 cm). The measurements were done at ~23 °C in a room 
with controlled temperature. Each CD spectrum is the result of six accumulations recorded in 
degrees. The following acquisition parameters were used: data pitch, 0.5 nm; bandwidth, 2.0 nm; 
response, 2 s and scan speed, 50 nm/min. Samples for CD analysis were obtained after disrupting the 
chitosan-coated insulin-loaded NPs in PBS (USP 30), pH 7.4 and ultrasounds. The insulin 
concentration of every sample was normalized to 1 mg/mL and compared with equal concentrations 
of non-encapsulated insulin.  
The CD signal values obtained at 208 nm were used to estimate the α-helical (%) content of the 
protein [30,31]. CD measurements were expressed as the mean residue ellipticity (MRE in deg cm2 
dmol−1), calculated from Equation 3: 
 
    =
   (    )
   ×    ×   
 (3) 
where N is the number of amino acid residues (51 for insulin), l is the length of the optical path (0.1 
cm) and Cp is the concentration of the protein. The α-helical content (%) is calculated from the MRE 
values at 208 nm, using Equation 4: 
 
  − ℎ     (%) = −
(         − 4000)
(33000 − 4000)
 ×  100 (4) 
2.2.6. In Vitro Release Assay 
A specific amount (10 mg) of double-coated insulin-loaded NPs were placed in 50 mL HCl (pH 
1.2), simulating gastrointestinal conditions, and always respecting sink conditions according to 
insulin’s solubility. The assay was performed at 37 °C with continuous stirring (100 rpm), in a 
magnetic multiplate (Heidolph MR3001, Heidolph, Schwabach, Germany), for 2 h. Aliquots (1 mL) 
were collected at 0.25, 0.5, 1, and 2 h and replaced using fresh medium to have a constant final 
volume. After this time period, the NPs were centrifuged (× g, 10 min) and the pellet was transferred 
to PBS at pH 6.8. Release assay continued at a speed of 100 rpm, at 37 °C, for 6 h. Aliquots (1 mL) 
were collected at 0.25, 0.5, 1, 2, 4, and 6 h, when the assay experiment was stopped. At the determined 
time points, the aliquots were collected and centrifuged (1500× g, 10 min), and the pellet was 
resuspended in the medium solution and returned to the release medium. The aliquots were 
analyzed and the concentration of insulin was determined by HPLC following the method previously 
described, in triplicate, and according to Equation 5 [29,31,32]: 
 
                 (%)  =
     +    ∑            
               ℎ                           
× 100 
(5) 
 
where Cn was insulin concentration at time n (time points), V was total volume of medium, Vi was 
volume of sample collected at time i, and Ci was concentration of insulin of sample collected at time 
i (initial time point). 
2.2.7. Ex-Vivo Mucoadhesion Study 
A TA-XTPlus Texture Analyser (Stable Micro Systems, Godalming, UK) equipped with a 5 k 
load cell was used for mucoadhesion tests [33]. A fresh Wistar chemically-induced diabetic rat 
(explained in section in vivo efficacy assay) small intestine was harvested and opened longitudinally, 
cleaned and cut into pieces that fit the movable cylindrical probe with the lumen side facing 
outwards, attached by a double-face tape to the probe. The rat intestine was also placed in a static 
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holder aligned with the probe, also attached by double-face tape. Between the intestine’s portions 
and in contact with the stationary part, the suspensions with NPs were placed: non-encapsulated 
insulin, uncoated NPs and double-coated NPs after digestion with pepsin, in equal concentrations of 
insulin. The double-coated NPs were incubated with pepsin, for 2 h at 37 °C, in order for the albumin 
to be digested, according to Pharmacopeia USP. The simulated gastric fluid was composed of 3.2 g/L 
of pepsin (with activity of 800 to 2500 units per mg of protein), sodium chloride, and hydrochloric 
acid. During the experiment, the movable part was lowered, until coming into contact with the 
mucosa, up to a force of 20 gf, and then raised at a constant speed of 0.25 mm/s.  
The displacement and the forces of compression and detachment were recorded. A curve of force 
(gf) versus time (s) was obtained for each experiment and the peak force of displacement (Fmax, gf) 
and area of the peak (AUC, gf.s) were acquired from this data. The experiments were performed five 
times for each sample. 
2.2.8. In Silico Mucoadhesion Analysis  
For mucoadhesion analysis of chitosan-coated NPs versus uncoated PLGA NPs, energetic and 
geometric stability of the polymer-mucin molecular complexes were determined using static lattice 
atomistic simulations (molecular mechanics simulations; Chemlite30, Hypercube Inc., Gainesville, 
FL, USA). The structures of PLGA and PEG were generated as natural bond angles while the ones of 
chitosan and glycosylated mucin (MUC) were generated using the saccharide building and sequence 
editor tools, respectively [34]. The individual molecules (PLGA, PEG, chitosan, and MUC) as well as 
the molecular complexes (PLGA-MUC and chitosan/PEG-MUC) were energy minimized and 
optimized using MM+ Force Field algorithm. For geometrical optimization, a Polak–Ribiere 
Conjugate Gradient method was employed until an RMS gradient of 0.001 kcal/mol was achieved 
[35]. 
2.2.9. Preliminary Safety Assessment 
In Vitro Assessment 
The safety of double-coated insulin-loaded NPs was assessed in vitro by a MTT assay performed 
in Caco2 cells, a human intestinal cell line commonly used for this type of assessment. These cells 
were kept in Dulbecco’s Modified Eagle’s medium (DMEM) high-glucose (4.5 g/L), supplemented 
with 10% fetal bovine serum and 100 IU/mL of penicillin and 100 µg/mL streptomycin (hereafter 
complete medium). Cells were maintained at 37 °C, with a 5% CO2 atmosphere, and checked every 2 
to 3 days, until a confluence of 80% was reached. Then, the cells were seeded in 96-well plates, at a 
concentration of 5.0 × 104 cells/mL. The cells were incubated with double-coated insulin-loaded and 
empty NPs, as well as non-encapsulated insulin. The concentrations tested, for both free and 
nanoencapsulated insulin, ranged from 0.0625 to 1 IU/mL, and the equivalent was tested for double-
coated empty NPs. After 24 h, complete medium was removed, the cells were washed with phosphate 
buffered saline (PBS) and the MTT solution in incomplete medium (0.5 mg/mL) was added. The cells 
were incubated for 4 h. After the incubation time, Dimethyl Sulfoxide (DMSO) was added in order 
to dissolve the formazan crystals. Absorbance was measured at 590 nm using a BioTek ELx800 
Absorbance Microplate Reader (BioTek Instruments, Inc., Winooski, VT, USA). 
In Vivo Preliminary Safety Assessment 
The in vivo preliminary safety assessment was performed in 18 male Wistar rats, weighing 
approximately 200 g. The animals were randomly separated into five groups: The test group (n = 5), 
to which 50 IU/kg of double-coated insulin-loaded NPs was orally administered; the vehicle control 
group (n = 5), which received empty double-coated NPs, by oral gavage; the negative control (n = 2), 
which received PBS orally; the oral insulin control (n = 3), that received 50 IU/kg of commercial insulin 
not incorporated in NPs, orally; and finally, the control for insulin’s activity (n = 3), to which 4 IU/kg 
of commercial insulin was subcutaneously administered. After 6 h, urine samples were collected from 
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all animals. The animals were then euthanized, plasma was collected, for hematological and 
biochemical analyses, and spleen, stomach, liver, intestine and kidney were harvested for histologic 
analysis. The organs were fixed in 10% formalin and embedded in paraffin. Five micrometer sections 
of each organ were prepared for hematoxylin-eosin staining. The stained slices were examined under 
an Olympus BX51 microscope (Olympus Corporation, Tokyo, Japan) and images were captured with 
NanoZoomer-SQ Digital slide scanner (Hamamatsu Photonics, Hamamatsu City, Japan). The urine 
samples collected were tested for leukocytes, urobilinogen, bilirubin, hematuria, nitrites, pH, density, 
proteinuria, glycosuria, and ketonic bodies, using Uritest 10 V Urinalysis Reagent Strips. Plasma 
samples were tested to quantify IL-6, ALT (to determine liver toxicity), creatine and urea (to 
determine kidney toxicity).  
2.2.10. In Vivo Efficacy Assay 
Diabetes Mellitus Induction 
In order to chemically induce diabetes mellitus in the male Wistar rats, streptozotocin (STZ), 
prepared in citrate buffer 0.1 M at pH 4.5 (UPS 30), was administered intraperitoneally (i.p., 65 mg/kg 
of body weight). After this procedure, animals were exposed to a 5% glucose solution during the 
night, in order to avoid reactional hypoglycemia, caused by the STZ. The animals were classified as 
diabetic when glycemia was higher than 300 mg/dL, measured on the third day post-administration 
[31,36]. The experimental protocol was started 10 days after STZ administration [29,36]. 
Study Design 
For the in vivo efficiency assay (n = 14), animals were randomly divided into three groups: The 
test group (n = 5), in which 50 IU/kg of NPs formulation was orally administered; the negative control 
group (n = 3), to which empty NPs were administered; in the third group, insulin was administered 
orally (n = 6). The formulation efficacy is translated by decreasing glycemia, glycemia was measured 
at the following time points: 30 min, 1, 2, 4, 6, and 8 h. Glycaemia levels were determined by 
measuring glucose oxidase/peroxidase, using a glucosometer (OneTouch® Verio®IQ, Milpitas, CA, 
USA). The animals were then sacrificed. The plasma to which the double-coated insulin-loaded NPs 
were administered was collected and its insulinaemia was determined by electrochemiluminescence 
immunoassay/(Roche-Cobas®). 
2.2.11. Statistical Analysis 
Each value is presented with a mean value ± SD. The statistical differences were evaluated with 
t-Student test and ANOVA. These tests allow to compare two or multiple groups, respectively. All 
analyses were conducted in GraphPad Prism Version 5.03 (GraphPad Software, San Diego, 
California, USA) and the differences were deemed significate at a p < 0.05. 
3. Results 
3.1. NPs Characterization: Size, Surface Charge, PI, Morphology, EE, and RY 
Mean size and PdI are shown in Table 1. Insulin-loaded NPs have a larger mean particle size 
than empty NPs. It is assumed that the increase in particle size was related to the encapsulation of 
insulin. Besides the particle size, there are other important parameters that contribute to an increase 
absorption of the NPs in the intestinal mucosa, such as NPs charge. This property was evaluated by 
measuring the NPs zeta potential in all phases of production, also shown in Table 1. A representative 
scheme of insulin NPs is displayed in Figure 1. The uncoated empty and uncoated insulin-loaded 
NPs (Figure 1A) showed a negative surface charge. This value was coherent with the PLGA charge 
at the considered pH, as previously reported [37]. The NPs charge was inverted to positive, in both 
empty NPs and insulin-loaded NPs by coating the NPs with chitosan, a cationic polymer, and PEG 
(Figure 1B). The final formulation was obtained after the BSA coating. The charge of the NPs coated 
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with BSA, both empty and insulin-loaded double-coated NPs (Figure 1C), remained positive, 
although slightly less positive. These results were as expected and coherent with what was described 
in previous studies [23,38]. 
 
Figure 1. Double-coated insulin-loaded nanoparticles (NPs) throughout the formulation and coating 
processes: (A) uncoated insulin-loaded poly (D, L-lactic-co-glycolic acid) (PLGA) NPs; (B) chitosan-
coated insulin-loaded PLGA NPs; and (C) double-coated insulin-loaded PLGA NPs. 
Table 1. Mean size, PdI and zeta potential throughout the different steps in formulation, for both 
empty and insulin-loaded NPs. All data is presented as mean ± SD (n = 3). 
Sample 
Mean size  
(nm) 
PdI 
Mean  
Zeta Potential  
(mV) 
Empty NPs 
Uncoated NPs 240 ± 2 0.110 ± 0.016 −39 ± 6 
Chitosan-coated NPs 328 ± 2 0.231 ± 0.015 +48 ± 8 
Double-coated NPs 233 ± 2 0.184 ± 0.016 +34 ± 8 
Insulin-loaded NPs 
Uncoated NPs 936 ± 4 0.449 ± 0.023 −49 ± 5 
Chitosan-coated NPs 819 ± 7 0.527 ± 0.028 +41 ± 13 
Double-coated NPs 560 ± 9 0.546 ± 0.030 +31 ± 3 
Figure 2 shows the images obtained by scanning electron microscopy for both double-coated 
empty and insulin-loaded NPs, where NPs seem to have a well-defined spherical shape. 
 
Figure 2. SEM micrographs of double-coated NPs. (A) Empty NPs. (B) Insulin-loaded NPs. Note in 
both cases the well-defined NPs spherical shape. Scale bars = 5 µm. 
The EE was 59.8 ± 2.6%, of the insulin used in the initial formulation. The RY was 80.6 ± 1.1%.  
3.2. Insulin Secondary Structure 
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Circular dichroism (CD) was used to evaluate the secondary structure of nanoencapsulated 
insulin, after being released, which was shown to remain intact, as illustrated in Figure 3, where it is 
observed the characteristic spectra of a protein with an alpha helix structure. Figure 3 presents CD 
spectra showing two peaks, which are characteristic of insulin’s CD spectrum, at 211 nm and 222 nm. 
An estimate of the α-helical content was done using the MRE at 208 nm. This yielded the following 
values 31%, 28%, and 27% for non-encapsulated insulin, uncoated NPs and chitosan-coated NPs, 
respectively. Thus, only a small decrease in the α-helical content was detected along the preparation 
and coating of NPs, suggesting no insulin fibrillation/aggregation among the conditions tested. 
Moreover, these findings were also supported by HPLC (observing the same retention time of insulin 
in all samples) and then after in vivo oral administration (section 3.7). 
 
Figure 3. Circular dichroism (CD) spectra of non-encapsulated insulin (___), uncoated NPs (---) and 
chitosan-coated NPs (…) in the Far UV range. 
3.3. In Vitro Release Assay 
This assay was performed in order to better understand insulin’s release profile in the 
gastrointestinal tract, and the results are shown in Figure 4. Temperature was kept at 37 °C and 
stirring was always constant. Firstly, the nanoencapsulated insulin was kept in acidic medium and 
aliquots were collected up to 2 h. In the acidic medium simulating gastric conditions, chitosan is 
probably starting to be dissolved at acidic pH and insulin release was 25.6 ± 3.4% after 2 h. For the 
neutral medium (mimicking the intestine), NPs are less coated and insulin immediately started to 
release and it was 100% released after 4 h.  
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Figure 4. Release assay for the double-coated insulin-loaded NPs in acidic medium until 2 h and 
conducted in neutral medium from 2 to 8 h, mimicking the pH range of the gastrointestinal tract (GIT). 
3.4. Mucoadhesion Study 
3.4.1. Ex-Vivo Mucoadhesion Study 
The maximum peak force of displacement (Fmax, gf) and area of the peak (AUC, gf.s) were 
obtained. The Fmax correlated well with AUC (r2 = 0.99). The results are shown in Figure 5. Pepsin 
digested double-coated NPs were shown to be more mucoadhesive than non-encapsulated insulin 
and uncoated NPs, having the highest value for both Fmax and AUC. Non-encapsulated insulin 
solution was found to promote the least mucoadhesive effect of all, as expected.  
 
Figure 5. The peak force of displacement (Fmax, gf) (A) and the area of the peak (AUC, gf.s) (B) obtained 
from the force versus time curves. The results are presented regarding the mean value ± respective 
SD (* p < 0.0332; **** p<0.0001). 
3.4.2. In Silico Mucoadhesion Analysis 
Table 2 and Figure 6A represent the geometrical preferences of NPs core and NPs coating with 
mucin (MUC) after molecular simulations, in vacuum, whereas Table 3 and Figure 6B represent the 
molecular, energy, and geometrical attributes inherent to PLGA-glycosylated MUC and 
chitosan/PEG-MUC molecular complexes, respectively. Both the polymer combinations—PLGA and 
chitosan/PEG—formed molecular complexes with MUC with –ve energy of stabilization hence 
confirming the polymer selection and application for the intended oral delivery. However, in case of 
PLGA-MUC molecular complex, all bonding energy terms (bond, angle, and dihedral energies) and 
two non-bonding energy contributions (H-bonding and electrostatic energy) were destabilized (Table 
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2). Although the PLGA chain showed good geometrical fit (ΔEvdW ≈ −33 kcal/mol); the torsional strains 
experienced by the polymer chain (ΔEangle ≈ +18 kcal/mol) retained the polymeric network out of the 
mucin matrix. Additionally, the PLGA chain not only showed partial intermolecular H-bond 
formation (…C-O…OH-C…) with MUC but also reduced the extent of intramolecular H-bonding 
within the MUC matrix (Figure 6A). With chitosan/PEG-MUC, the energy of stabilization was 
significantly higher (ΔE ≈ −54 kcal/mol) than PLGA-MUC with all component energies stabilized 
except angle and H-bonding contributions (Table 3). It is worth noting that the bond angle 
contribution energy in chitosan/PEG-MUC was much lower than PLGA-MUC as well as the bond 
stretching and torsional energies in chitosan/PEG-MUC showed favorable stabilization. In addition 
to this, stabilization of the van der Waals function (ΔE ≈ −24 kcal/mol) led to a close fit of the chitosan 
chains within the MUC matrix. The close geometrical fit so formed further induced electrostatic 
interactions (ΔE ≈ −35 kcal/mol) leading to formation of several intermolecular H-bonds such as      
…C-O-C…H-N…, …N-H…H-N…, and …O-H…H-O… and even intramolecular H-bonds within the 
MUC matrix (Figure 6B). The PEG chain also contributed to H-bonding with …C-OH…HO-C… 
interactions with the end group. Although the H-bonding function was partially destabilized (ΔEangle 
≈ +0.322 kcal/mol), which may be due to amphiphilic nature of the PEG chain, the overall non-
bonding interactions were counter-stabilized by the van der Waals and induced electrostatic 
interactions.  
Table 2. Inherent energy attributes of poly (D, L-lactic-co-glycolic acid)–mucin (PLGA–MUC) 
conjugate calculated using static lattice atomistic simulations in vacuum. 
Energy MUC PLGA PLGA–MUC 
ΔE a 
Structure Stabilizing Structure Destabilizing 
Total b −166.812 2.638 −171.699 −7.53  
Bond c 5.474 0.288 6.149  0.39 
Angle d 70.351 2.534 90.682  17.80 
Dihed e 55.173 0.885 59.13  3.07 
vdW f −29.066 −1.062 −62.948 −32.82  
H-bond g −7.096 −0.007 −6.724  0.38 
Elec h −261.649 0.000 −257.987  3.66 
a ΔE(A/B) = E(A/B) – [E(A) + E(B)]; b Total steric energy for an optimized structure; c Bond stretching 
contributions; d Bond angle contributions; e Torsional contribution arising from deviations from 
optimum dihedral angles; f Van der Waals interactions; g Hydrogen-bond energy function; h 
Electrostatic interactions. 
Table 3. Inherent energy attributes of chitosan/PEG-MUC conjugate calculated using static lattice 
atomistic simulations in vacuum. 
Energy MUC Chitosan PEG 
Chitosan/PEG-
MUC 
ΔE a 
Structure 
Stabilizing 
Structure 
Destabilizing 
Total b −166.812 8.822 10.127 −201.742 −53.879  
Bond c 5.474 1.077 0.158 6.706 −0.003  
Angle d 70.351 6.058 0.703 82.729  5.617 
Dihed e 55.173 8.755 6.001 66.450 −3.479  
vdW f −29.066 5.920 3.264 −43.716 −23.834  
H-bond g −7.096 0.000 0.000 −6.774  0.322 
Elec h −261.649 −12.988 0.000 −307.137 −32.5  
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a ΔE(A/B) = E(A/B) − [E(A) + E(B)]; b Total steric energy for an optimized structure; c Bond stretching 
contributions; d Bond angle contributions; e Torsional contribution arising from deviations from 
optimum dihedral angles; f van der Waals interactions; g Hydrogen-bond energy function; h 
Electrostatic interactions. 
 
Figure 6. Representation of the geometrical preferences of (A) PLGA-MUC; (B) Chitosan/PEG-MUC 
after molecular mechanics simulations in vacuum [Colour code for elements: C = cyan; H = white; O 
= red; N = blue]. PLGA: tube rendering; MUC: stick rendering and yellow second. 
3.5. Preliminary Safety Assessment of Double-Coated Insulin-Loaded NPs 
In Vitro Preliminary Safety Assessment (MTT) 
In order to preliminarily evaluate the safety of the double-coated insulin-loaded NPs, its 
cytotoxicity activity was assessed by performing a MTT assay. MTT is commonly technique to access 
the mitochondrial activity [39]. Caco2 cells were incubated with the double-coated insulin-loaded 
and empty NPs, as well as non-encapsulated insulin, and the results, presented as % of cell viability, 
are shown in Figure 7. Double-coated empty NPs led to a slight decrease in cell viability, although 
the lowest mean value was around 85%, at a concentration of 0.5 IU/mL. Looking at the results 
regarding the double-coated insulin-loaded NPs, we can see the same tendency, with a mean value 
of around 87% of viable cells. 
 
Figure 7. Cell viability (%) of cells treated with double-coated insulin-loaded NPs (empty columns), 
double-coated empty NPs (grey columns) and non-encapsulated insulin (full columns). The NPs 
concentrations tested ranged from 0.0625 to 1 IU/mL. The results were presented regarding the mean 
value ± SD (* p < 0.0332; ** p < 0.0021; *** p < 0.0002; **** p < 0.0001). 
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3.6. In Vivo Preliminary Safety Assessment 
Animals’ behavior remained unchanged, showing no signs of distress. Different parameters 
were evaluated in the urine (i.e., leucocytes, urobilinogen, bilirubin, hematuria, nitrite, pH, density, 
proteinuria, glycosuria and ketonic bodies), and the results are shown in Table 4. Looking at the 
results, it is to note that, apart from hematuria, proteinuria and ketonic bodies, none of the parameters 
have changed, when compared to the negative control (PBS) group. Both control and test groups had 
positive cases of proteinuria which might be attributable to the NPs formulation. Although some rats 
from the insulin-loaded NPs test group showed an increase in proteinuria, it was never higher than 
15 mg/mL, which is still very low and thus, deemed an acceptable proteinuria. Test group did not 
present ketonic bodies. In the group that orally received empty NPs, an increase hematuria was also 
observed in some animals, but its hematuria was lower than the one observed for the control group. 
Table 4. Status of the different parameters evaluated in the urine of the rats of the different groups. 
 
Insulin-loaded 
NPs  
(n = 5) 
Empty NPs  
(n = 5) 
Non-
encapsulated 
insulin, p.o.  
(n = 3) 
PBS  
(n = 2) 
Leucocytes - - - - 
Urobilinogen N N N N 
Bilirubin - - - - 
Hematuria +/- +/- - +/- 
Nitrite - - - - 
pH 5.4 5.9 5.3 5.5 
Density 1.03 1.02 1.03 1.03 
Proteinuria +/- +/- +/- +/- 
Glycosuria - - - - 
Ketonic bodies - - +/- +/- 
+, one positive case; −, negative result; N, no change. 
Figure 8 shows representative images of the organs collected for histological analysis. All organs 
showcased their physiological traits, without pathological alterations. Thus, the double-coated 
insulin-loaded NPs did not cause acute organ toxicity to the different organs tested (i.e., spleen, 
stomach, liver, intestine, and kidney), deeming the formulation as being safe for oral administration. 
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Figure 8. Histological images (spleen and liver with 200× microscopic approach; stomach, intestine 
and kidney with 100× microscopic approach) of the organs removed for analysis after necropsy (i.e., 
spleen, stomach, liver, intestine, and kidney). All images are representative of the harvested organs, 
which showed no histologic alterations (H&E staining). 
Table 5 summarizes the main results of the biochemical analysis conducted to quantify the ALT, 
creatinine, urea and IL-6, serum levels of the rats in the different groups, evaluating general and 
organ-specific (kidney and liver) toxicity. By comparing the results of the group treated with double-
coated insulin NPs to the negative control (PBS), no toxicity was seen. Although ALT was slightly 
increased, it was still between the reference interval for male Wistar rats (24–29 IU/L [40]), and all the 
other parameters did not change when compared with the control. Thus, the double-coated insulin-
loaded NPs did not cause any acute toxicity, either general or organ-specific, neither inflammatory 
response, thus reinforcing the safety of the formulation for oral delivery. 
Table 5. Serum levels of ALT, creatinine, urea, and IL-6, of the rats of the different groups. The results 
were presented regarding the mean ± SD. 
Formulation and number of animals 
ALT 
(U/L) 
Creatinine 
(mg/dL) 
Urea 
(mg/dL) 
IL-6 
(ng/dL) 
PBS 
(n = 2) 
30.5 ± 12.0 0.39 ± 0.03 37.0 ± 9.9 < 1.5 
Oral non-encapsulated Insulin 
(n = 3) 
34. 7 ± 3.8 0.38 ± 0.02 37. 7 ± 6.5 < 1.5 
SC non-encapsulated Insulin 
(n = 2) 
21.0± 4.2 0.37± 0.01 41.0± 1. 8 < 1.5 
Double-coated Insulin-loaded NPs 
(n = 5) 
34.6 ± 12.1 0.40 ± 0.02 37.4 ± 2.8 < 1.5 
Empty NPs 
(n = 5) 
35.6 ± 14.2 0.35 ± 0.06 37.2 ± 1.9 < 1.5 
3.7. In Vivo Efficacy Assay 
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In order to test the treatment potential of this double-coated insulin-loaded NPs in vivo, the 
formulation was orally administered to diabetic Wistar rats. As insulin’s efficacy is translated by its 
ability to decrease glycemia values, the glycemia was recorded and the results are shown in Figure 
9. It was observed that the diabetic rats treated with double-coated insulin-loaded NPs had a 
significant decrease in glycemia throughout all time points, in comparison to orally non-encapsulated 
insulin. The nanoencapsulated insulin led to a sharp decrease in glycemia after 2 h, being that the 
glycemia of the diabetic rats decreased by between the 4th and 6th hour. After the final time point, 
animals were sacrificed and the test group’s insulinemia was measured, having a mean insulinemia 
(human insulin, i.e., our exogenous insulin) of 0.6 µIU/mL, significantly higher than the control group 
(as expected, there was no increase in plasma insulin in the control group). 
 
Figure 9. Glycaemia levels of diabetic rats treated with commercialized insulin (…, n = 6, 50 IU/kg), 
empty (---, n = 3, equivalent amount) and double-coated insulin-loaded NPs (___, n = 5, 50 IU/Kg), 
orally administered. The results are presented regarding their mean ± SD (* p < 0.0332; ** p < 0.0021; 
*** p < 0.0002; **** p <0.0001). 
4. Discussion 
Insulin-loaded NPs were successfully prepared and characterized regarding its mean size, PdI 
and surface charge, morphology and delivery efficiency. The formulated double-coated insulin-
loaded NPs had a mean diameter smaller than 600 nm. It is well known that the overall surface area 
of the particles increases by several orders of magnitude when the particle size is on the order of the 
nanometer. However, the ideal particle size for the NPs to be absorbed by the intestinal mucosa is 
still not consensual. Some studies have shown that the particle size should be smaller than 5000 nm 
in order to be absorbed in the intestinal mucosa [39], whilst other studies states the limit should be 
between 130 and 950 nm or, in order to optimize NPs uptake by M cells, a mean size less than 500 nm 
[41]. Altogether, the previous studies presented lead us to believe that the prepared formulation will 
be uptaken by M cells in the Peyers patches [41], as the obtained particles are of a smaller size than 
the size limits mentioned. Furthermore, during the formulation process an accentuated decrease in 
size was seen when the BSA coating was added. This is due to the BSA coating causing a closure of 
the void spaces present throughout the NP, compacting it, and was also seen in other studies using 
similar coatings [22]. Nonetheless, the size of the double-coated insulin-loaded NPs will decrease 
throughout its path in the GI tract and after being absorbed, due to digestion of the BSA coating and 
loss of chitosan coating. On the other hand, NPs surface charge is also very detrimental for particle 
absorption in the intestine mucosa, as positively-charged particles are more adherent to the intestine 
mucosa [41]. In general, mucus is mainly composed of water (~95% w/w), mucins (~0.2% to 5.0% 
w/v), salts (~0.5% to 1.0% w/w), globular proteins (~0.5% w/v), lipids (1%–2% w/w), DNA, cells and 
cellular debris [42]. The high content in sialic acid and sulphate in most mucin glycoproteins confer 
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a strongly net-negative surface charge [42]. NPs surface charge was accessed by measuring the zeta 
potential of empty NPs and insulin-loaded NPs, throughout the addition of the different coatings. 
The results shown in Table 1 indicate that the PLGA NPs were successfully coated, as we can see the 
change in zeta potential throughout the application of the different coatings. Chitosan was successful 
in inverting the NPs zeta potential from negative (uncoated) to positive. Although the final charge, 
when the BSA coating is added to the NPs, is slightly less positive than when the PLGA NPs are 
coated with chitosan and PEG, when the particles reach the intestine mucosa it is expected that the 
BSA coating will no longer be present as previously described [22,23]. Thus, when the NPs reach this 
region its surface charge will be positive, which is intended, as positively-charged particles are more 
adherent to the intestine mucosa, by interactions with mucins, negatively-charged glycosylated 
proteins [10], and, consequently, it might increase the residence time of the NPs in the mucosa, 
enhancing the bioavailability of the insulin [22,23]. 
NPs morphology was assessed by SEM and a well-defined spherical shape of the formulated 
NPs, characteristic of the used polymers, was observed [25]. The spherical shape of the NPs is 
important as it allows a greater contact surface with the intestine mucosa, facilitating the uptake of 
the NPs [43]. Previous studies have already taken advantage of NPs spherical shape to achieve higher 
absorption of orally insulin [29,43,44]. 
Insulin-loaded PLGA NPs were successfully prepared and coated with chitosan-PEG and BSA. 
The obtained encapsulation efficiency was of 60%. Although a higher value would be preferable, 
some steps during the formulation process might have caused lower encapsulation efficiency. The 
obtained value might be due to the pH oscillations, which has been proven to influence encapsulation 
efficiency [29], caused by the addition of the different coatings. Insulin has an isoelectric point of 5.3 
and therefore it is positively charged at pH 4.5, which might lead to interactions between the different 
materials, namely BSA, chitosan, PLGA and insulin itself, which can cause some diffusion of insulin 
from inside to outside of NPs [36,45]. Furthermore, insulin is hydrophilic, thus it has higher affinity 
to the aqueous (external) phase, which increases the odds of it diffusing out of the polymeric matrix. 
Finally, the stirring rate used during the addition of the coatings might have also caused some insulin 
loss, although without change in its biological activity. Nevertheless, a recovery yield of 81% was 
obtained, which will undoubtedly have a good impact at industrial scale level. 
Post-encapsulation insulin was accessed by CD analysis to evaluate insulin’s secondary 
structure as for protein drugs to be biologically efficient, their structural integrity must be kept. As 
Brange et al. stated, insulin’s secondary structure is characteristically composed by alpha helix motifs 
and the maintenance of the structure stability allows insulin to perform its pharmacological activity 
[46]. Analyzing the results of the CD shown in Figure 3, we can observe very close CD spectra, 
suggesting that insulin’s secondary structure was preserved during or after the encapsulation 
process. Although there are other techniques available for the assessment of proteins’ secondary 
structure, CD is a very suitable technique and commonly used due to being a faster technique and 
requiring a smaller sample [47–49]. Regardless of CD results deeming post-encapsulation insulin as 
being active, its activity was also confirmed in vivo, by analyzing the decrease of glycemia in diabetic 
rats after oral administration of the double-coated insulin-loaded NPs. Lastly, the coating with BSA 
was effective in maintaining insulin’s activity after oral dosing like our group had already 
demonstrated [22,30]. The presence of active insulin was also confirmed by measuring the 
insulinemia in diabetic animals to which double-coated insulin-loaded NPs was administered, 
supporting the presence of human insulin in its blood flow. 
PLGA is a FDA approved hydrophobic polymer that allows total release of insulin after 
administration, due to insulin’s hydrophilic nature, and is easily degradable by endocytosis 
[7,12,50,51]. The degradation products of PLGA are also easily included in Krebs cycle [52]. However, 
due to their negative charge, insulin-loaded PLGA NPs have poor adhesion to the intestinal wall. 
This fact led us to an additional coating of our NPs with a polycationic polymer, such as chitosan. 
With chitosan, we will expect that mucoadhesion in the intestine mucosa increases, contributing to 
an increase in the permanence period of the insulin in the mucosa [7,12], facilitating its passage 
through the epithelial cellular junctions [53]. This fact was confirmed by ex-vivo assessment where 
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chitosan-coated NPs have the highest values for both Fmax and AUC. Simulations of molecular 
interaction in silico conducted in vacuum provided interesting corroboration with the ex-vivo 
findings. Although both the polymer combinations, PLGA and chitosan/PEG, formed molecular 
complexes with MUC, the energy of stabilization was significantly higher for chitosan/PEG-MUC 
(ΔE ≈ −54 kcal/mol) than for PLGA-MUC (ΔE ≈ −7.5 kcal/mol). These results confirm the preferable 
mucoadhesive profile of chitosan/PEG-coated NPs as compared to the uncoated PLGA NPs, as 
predicted in the ex-vivo results. 
The development of suitable and biocompatible drug delivery systems is a prerequisite, 
especially for a chronic disease like diabetes [17]. MTT assay was done to assess cytotoxicity and 
exhibited good results as it demonstrated that double-coated insulin-loaded NPs did not alter cell 
viability. Regarding empty NPs, the lowest mean value of viability found was 85%. This value of cell 
viability of the empty NPs could be attributed to the NPs’ structure by itself as previously 
demonstrated [54], and it is not noticeable in insulin-loaded NPs possibly due to the insulin’s 
presence, since insulin can act as a growth factor, promoting cell growth. 
In vitro assays are extremely useful tools, but they cannot accurately predict the in vivo behavior 
of all formulations. Therefore, an in vivo preliminary safety assessment study was also performed. 
To assess NPs formulation safety when orally administered, animals’ behavior was closely monitored 
during the test. No death occurred after the treatment. When comparing the urine tests results, 
biochemical analysis and histological images of insulin-loaded NPs and negative control group (PBS 
group), it is displayed that there was no obvious damage to animals. Thus, in vivo studies results 
were in agreement with in vitro MTT assay, i.e., our insulin-loaded NPs are safe for oral 
administration. 
The presented research entails to develop an insulin formulation suitable for oral delivery as an 
alternative treatment for the commercially available subcutaneous insulin. Oral administration is 
considered as the best route of administration because of its cost-effectiveness and well-established 
acceptability. In addition, it allows avoiding the use of injections. An additional advantage is related 
to a more physiological action by its direct effect on hepatic glucose production. If the insulin would 
be absorbed in the gut, insulin would be transferred directly toward the liver. At the liver, the 
exogenously insulin would control hepatic glucose production to the same extent similarly as this is 
induced by endogenously insulin in healthy subjects. This more physiological delivery would be 
associated with reduced peripheral hyperinsulinemia in contrast to SC administration. In terms of 
pharmacokinetics, as representative example, in a small study made by Cernea et al. 2004 [55], male 
subjects under euglycemic conditions, oral insulin spray was associated with a higher Cmax, shorter 
Tmax, and faster time to peak glucose uptake compared with SC insulin. The short Tmax and the 120-
min duration of effect of oral insulin spray suggest it may be a promising alternative for fulfilling 
meal-related insulin requirements in persons with diabetes. Another encouraging study was done 
with a few number of subjects with 8 mg of oral insulin formulation [56]. Administration of an oral 
form of insulin in the fasted state demonstrated a significant effect on insulin absorption. This 
substantial effect was seen by a reduction of blood glucose (7%–37%), decline in C-peptide levels 
(13%–87%), as well as an elevation of insulin level (20%–120%). It was noticed that some subjects 
developed symptomatic hypoglycemia. Insulin formulations were well tolerated. No adverse or 
serious adverse events have been reported. Therefore, we aimed to develop a new oral insulin 
formation and to evaluate if the developed formulation is effective when administered orally. The 
results showed that the formulation was effective in reducing glucose levels of diabetic rats (Figure 
9). A previous study comparing the subcutaneous administration of 4 IU/kg insulin with oral 
administration of 50 IU/kg of nanoencapsulated insulin coated with chitosan and albumin in Wistar 
diabetic rats has shown that the NPs formulation achieved a reduction in glycemia of 28% between 
the 2nd and 4th hour, and 48% between the 8th and 12th hour [29]. When compared to other studied 
formulations, the formulation reported herein has shown preferable characteristics. Many of the 
previously developed formulations for oral delivery of insulin have negative surface charge [50–54], 
not favoring the NPs’ interactions with mucins, and thus not promoting adherence to the intestine’s 
mucosa [10,22,23]. Besides having a positive surface charge, the double-coated insulin-loaded NPs 
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showed to interact with mucin, therefore proving its mucoadhesive properties, as observed both by 
the in silico simulations of molecular interaction conducted in vacuum, and by the ex vivo 
experiments. The double-coated formulation also showed lower insulin release in gastric-like 
conditions after 2 h (22.6%) than other formulations intended for oral delivery of insulin with half 
and more than half of the encapsulated insulin being released in stomach-like conditions after two 
hours (~50% [57], ~60% [58]), suggesting that, unlike other formulations, our double-coated insulin-
loaded NPs formulation has the potential to deliver insulin in the proper target—the gut. Moreover, 
our formulation was more efficient in lowering diabetic-rats than others: while our double-coated 
insulin loaded NPs induced a 50% glycemia decrease 8 h post-oral administration, other studied 
formulations reported smaller and later hypoglycemic effects, to less than 60% after 12 h [59] or 24 h 
[60] post-oral administration. Furthermore, when compared to other chitosan-based insulin-loaded 
NPs, the developed formulation had higher encapsulated efficiency, was more resistant to gastric-
like conditions or/and achieved higher decrease in glycemia, at 4 h, than what was seen for other 
chitosan-based formulations of insulin nanoparticles [61–63]. 
5. Conclusions 
Oral insulin replacement therapy remains a very appealing alternative to subcutaneous 
injections for patients with diabetes mellitus. However, it seems that the search for an acceptable 
insulin oral formulation is much more difficult than initially thought. After decades of failed attempts 
to produce an oral insulin formulation, the number of published clinical trial reports so far is limited. 
The hope clearly is to see more clinical data. A suitable drug carrier is important to ensure site-specific 
sustained drug delivery. 
As described herein, our double-coated insulin-loaded NPs formulation showed to be efficient 
in reducing the glycemia up to 50% in chemically-induced diabetic rats and it is safe. Additionally, 
the encapsulation was effective and the method of encapsulation did not alter the insulin’s secondary 
structure. So, it is expected that the drug maintains its integrity when it reaches its biological target. 
Furthermore, it was proved in the in vitro assays that by encapsulating insulin and coating the NPs 
with two different layers, insulin was protected from the hostile environment of the GIT. Moreover, 
the ex-vivo study showed that the chitosan coating exerts its mucoadhesiveness, correlating with the 
in silico analysis. 
Thus, these double-coated insulin-loaded NPs might provide a more efficient and safer platform 
for delivering insulin by mimicking physiologic processes and directly deliver insulin to the liver 
rather than via the bloodstream. A great amount of work still remains to be done, but like many other 
examples in other therapeutic areas, nanomedicine brings new hope to succeed in obtaining an oral 
treatment of insulin available to diabetic patients. 
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